Chin N X, Neu H C
Antimicrob Agents Chemother. 1987 Mar;31(3):480-3. doi: 10.1128/AAC.31.3.480.
BMY-28100 is a new oral cephalosporin which had in vitro activity superior to that of cephalexin and cefaclor against staphylococci, beta-hemolytic streptococcal species, and Streptococcus pneumoniae. It inhibited beta-lactamase-producing Haemophilus influenzae, Neisseria gonorrhoeae, 50% of Streptococcus faecalis isolates, Listeria monocytogenes, and 50 to 75% of Escherichia coli and Klebsiella species at less than or equal to 8 micrograms/ml, but high producers of beta-lactamase were resistant. Enterobacter, Citrobacter, Morganella, Providencia, and Pseudomonas species and Bacteroides fragilis were resistant. BMY-28100 was more stable than cefaclor against hydrolysis by beta-lactamases.
BMY - 28100是一种新型口服头孢菌素，其体外活性优于头孢氨苄和头孢克洛，对葡萄球菌、β - 溶血性链球菌和肺炎链球菌均有活性。它能抑制产β - 内酰胺酶的流感嗜血杆菌、淋病奈瑟菌、50%的粪肠球菌分离株、单核细胞增生李斯特菌以及50%至75%的大肠杆菌和克雷伯菌属，浓度小于或等于8微克/毫升，但高产β - 内酰胺酶的菌株具有耐药性。阴沟肠杆菌、柠檬酸杆菌、摩根菌属、普罗威登斯菌属、假单胞菌属和脆弱拟杆菌均耐药。BMY - 28100比头孢克洛更稳定，不易被β - 内酰胺酶水解。
